Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor

2006 ◽  
Vol 17 (3) ◽  
pp. 160-161 ◽  
Author(s):  
Francesca Santoro ◽  
Emanuele Cozzani ◽  
Aurora Parodi
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Adverse Effects ◽  
Growth Factor Receptor ◽  
Egfr Inhibitor ◽  
Epidermal Growth

Exploring Epidermal Growth Factor Receptor (EGFR) Inhibitor Features: The Role of Fused Dioxygenated Rings on the Quinazoline Scaffold

2010 ◽  
Vol 53 (4) ◽  
pp. 1862-1866 ◽  
Author(s):  
Adriana Chilin ◽  
Maria Teresa Conconi ◽  
Giovanni Marzaro ◽  
Adriano Guiotto ◽  
Luca Urbani ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Egfr Inhibitor ◽  
Epidermal Growth

scholarly journals Epidermal growth factor receptor (EGFR) inhibitor induced purpuric drug eruption

Medicine ◽  
2019 ◽  
Vol 98 (47) ◽  
pp. e18112 ◽  
Author(s):  
Szu-Yun Fang ◽  
Chieh-Shan Wu ◽  
Yi-Shan Liu ◽  
Kai-Che Wei
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Drug Eruption ◽  
Growth Factor Receptor ◽  
Egfr Inhibitor ◽  
Epidermal Growth

scholarly journals Epidermal growth factor receptor inhibitor therapy for recurrent respiratory papillomatosis

F1000Research ◽  
2013 ◽  
Vol 2 ◽  
pp. 202 ◽  
Author(s):  
Matthew M. Moldan ◽  
Bruce C Bostrom ◽  
Robert J Tibesar ◽  
Timothy A. Lander ◽  
James D. Sidman
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Adjuvant Therapy ◽  
Growth Factor Receptor ◽  
Recurrent Respiratory Papillomatosis ◽  
Inhibitor Therapy ◽  
Egfr Inhibitors ◽  
Egfr Inhibitor ◽  
Epidermal Growth

The epidermal growth factor pathway has been implicated in various tumors, including human papillomavirus (HPV) lesions such as recurrent respiratory papillomatosis (RRP). Due to the presence of epidermal growth factor receptors in RRP, epidermal growth factor receptor (EGFR) inhibitors have been utilized as adjuvant therapy. This case series examines the response to EGFR inhibitors in RRP. Four patients with life-threatening RRP were treated with EGFR inhibitors. Operative frequency and anatomical Derkay scores were calculated prior to, and following EGFR inhibitor treatment via retrospective chart review. The anatomical Derkay score decreased for all four patients after initiation of EGFR inhibitor therapy. In one patient, the operative frequency increased after switching to an intravenous inhibitor after loss of control with an oral inhibitor. In the other patients there was a greater than 20% decrease in operative frequency in one and a more than doubling in the time between procedures in two.  This study suggests that EGFR inhibitors are a potential adjuvant therapy in RRP and deserve further study in a larger number of patients.

Sign in / Sign up

Export Citation Format

Share Document